Banamine Transdermal is a drug owned by INTERVET, INC. It is protected by 1 US drug patent filed in 2032. All patents are active. Details of Banamine Transdermal’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US9006272 | Active | |
Exclusivity Information
Banamine Transdermal holds 1 exclusivity out of which 0 have expired. Its last outstanding exclusivity is set to expire in 2025. Details of Banamine Transdermal's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCI | Dec 23, 2025 |
About Banamine Transdermal
Banamine Transdermal is a drug
owned by INTERVET, INC.
Banamine Transdermal uses
Flunixin as the active
ingredient.
Active Ingredient:
Banamine Transdermal uses
Flunixin as the active ingredient.
Check out other Drugs and Companies using
Flunixin ingredient.